Astrea Bioseparations Acquires Delta Precision Ltd.
Astrea Bioseparations (Cambridge, UK) has announced the acquisition of Delta Precision Ltd. (Stonehouse, UK), a manufacturer of chromatography columns for the biotechnology and pharmaceutical industries. This acquisition will allow Astrea Bioseparations to expand its product offering to include a range of high-performance chromatography columns for biomanufacturing, alongside the company’s existing portfolio of bioprocessing resins, reusable columns, and prepacked single-use columns.
“We are delighted to welcome the Delta team into the fold. The acquisition of Delta is another step forward in Astrea Bioseparations’ rapid expansion to support the biopharmaceutical manufacturing field,” said Terry Pizzie, CEO of Astrea Bioseparations.
Geoff Parnell, co-founder and MD at Delta Precision, commented, “We look forward to joining the Astrea Bioseparations family, further cementing the long-standing relationship between the two companies. We are confident that our expertise in column manufacturing will complement and accelerate the Astrea Bioseparations business and customer reach.”
For more information, please visit: www.astreabioseparations.com or
www.delta-precision.co.uk
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
